Quick Answer
Chemomab Therapeutics Ltd. reported Net Income of -$8.99 million for fiscal year 2025.
Chemomab Therapeutics Ltd. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$8.99M +35.5% |
-$13.95M +42.4% |
-$24.22M +12.4% |
-$27.65M -121.6% |
-$12.48M -109.7% |
-$5.95M +78.1% |
| Diluted EPS | $0.02 -53.8% |
$0.04 -62.1% |
$0.10 -14.9% |
$0.12 +101.7% |
$0.06 | — |
| Total Assets | $13.81M -18.6% |
$16.96M -23.4% |
$22.15M -48.6% |
$43.06M -33.1% |
$64.35M +415.8% |
$12.48M -36.8% |
| Cash and Equivalents | $7.56M +24.6% |
$6.07M -34.7% |
$9.29M -31.3% |
$13.52M -11.0% |
$15.19M +30.1% |
$11.67M -33.6% |
| Stockholders Equity | $12.33M -8.9% |
$13.54M -20.4% |
$17.00M -53.1% |
$36.22M -41.1% |
$61.47M +469.0% |
$10.80M -12.7% |
| R&D Expense | $5.83M -48.5% |
$11.33M -38.4% |
$18.38M +8.3% |
$16.98M +168.0% |
$6.33M +35.2% |
$4.68M -64.8% |
| Shares Outstanding | — | — | — | — | — | 37.10M +0.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | March 31, 2023 | -$8.75M | -71.5% | -8.3% |
| Diluted EPS | March 31, 2023 | $0.04 | +81.8% | +14.3% |
| Total Assets | March 31, 2023 | $35.01M | -42.6% | -18.7% |
| Cash and Equivalents | March 31, 2023 | $20.77M | +50.2% | +53.6% |
| Stockholders Equity | March 31, 2023 | $27.95M | -51.2% | -22.8% |
| R&D Expense | March 31, 2023 | $6.89M | +150.9% | +27.0% |
| Shares Outstanding | March 31, 2023 | 232.64M | +2.0% | +0.0% |
- Chemomab Therapeutics Ltd. reported Net Income of -$8.99 million for fiscal year 2025.
- Chemomab Therapeutics Ltd. showed an increase of +35.5% in Net Income compared to the prior fiscal year.
- Chemomab Therapeutics Ltd. reported Diluted EPS of $0.02 per share for fiscal year 2025.
- Chemomab Therapeutics Ltd. showed a decrease of -53.8% in Diluted EPS compared to the prior fiscal year.
- Chemomab Therapeutics Ltd. reported Total Assets of $13.81 million for fiscal year 2025.
- Chemomab Therapeutics Ltd. showed a decrease of -18.6% in Total Assets compared to the prior fiscal year.
- Chemomab Therapeutics Ltd. reported Cash and Equivalents of $7.56 million for fiscal year 2025.
- Chemomab Therapeutics Ltd. showed an increase of +24.6% in Cash and Equivalents compared to the prior fiscal year.
- Chemomab Therapeutics Ltd. reported Stockholders Equity of $12.33 million for fiscal year 2025.
- Chemomab Therapeutics Ltd. showed a decrease of -8.9% in Stockholders Equity compared to the prior fiscal year.
- Chemomab Therapeutics Ltd. reported R&D Expense of $5.83 million for fiscal year 2025.
- Chemomab Therapeutics Ltd. showed a decrease of -48.5% in R&D Expense compared to the prior fiscal year.
- Chemomab Therapeutics Ltd. reported Shares Outstanding of 37.10 million shares for fiscal year 2020.
- Chemomab Therapeutics Ltd. showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: